stockrowLivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.89%
- EPS
- +27.0%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) P/S ratio
As of 6 November 2026, LivaNova PLC (LIVN) trades at a P/S ratio of 3.3×. Over the past ten years it has ranged from 1.4× (April 2025) to 6.0× (October 2015); the current reading is higher than 58% of that period. That is above the Medical Devices industry median of 2.5× and in line with the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 2.4× | 20.66% |
| FY2024 | 2.0× | (15.20%) |
| FY2023 | 2.4× | (18.17%) |
| FY2022 | 2.9× | (32.45%) |
| FY2021 | 4.3× | 24.16% |
| FY2020 | 3.4× | 2.38% |
| FY2019 | 3.4× | (16.06%) |
| FY2018 | 4.0× | 5.36% |
| FY2017 | 3.8× | 65.73% |
| FY2016 | 2.3× | (61.71%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 2.8× | (8.96%) |
| Jun 2026 | 3.1× | 26.68% |
| Mar 2026 | 2.4× | 0.29% |
| Dec 2025 | 2.4× | 13.99% |
| 45 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| ITGR Integer Holdings Corporation compare | 2.4× |
| BRKR Bruker Corporation compare | 2.5× |
| NEOG Neogen Corporation compare | 2.9× |
| LIVN LivaNova PLC | 3.4× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.8× |
| HAE Haemonetics Corporation compare | 4.1× |
| IRTC iRhythm Holdings, Inc. compare | 5.1× |
| AXGN AxoGen, Inc. compare | 10.1× |
| TXG 10x Genomics compare | 12.4× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement